Cart (0 Items)
Your cart is currently empty.
View ProductsSize | |
---|---|
Brand | |
Product type | |
Clonality | |
Expression system | |
Applications |
Product name | Ocaratuzumab Biosimilar - Anti-MS4A1, CD20 mAb - Research Grade |
---|---|
Source | CAS 1169956-08-4 |
Species | Humanized |
Expression system | Mammalian cells |
Purity | >85% |
Buffer | PBS buffer PH7.5 |
Delivery condition | Blue ice (+4°C) |
Delivery Time | 3-5 days if in stock; 3-5 weeks if production needed |
Storage condition | store at -80°C |
Brand | ProteoGenix |
Applications | ELISA,WB |
Aliases /Synonyms | Ocaratuzumab,AME-133v,LY2469298,MS4A1, CD20,anti-MS4A1, CD20 |
Reference | PX-TA1298 |
Note | For research use only. Not suitable for clinical or therapeutic use. |
Isotype | IgG1-kappa |
Clonality | Monoclonal Antibody |
Ocaratuzumab is used for the treatment of cancer and autoimmune disorders. The antibody has been designed with an increased affinity to the CD20 antigen on B-lymphocytes, to enhance antibody-dependent cell-mediated cytotoxicity (ADCC).
Immobilized Human CD20/MS4A1 recombinant protein (cat. No.PX-P6274) at 0.5µg/mL (100µL/well) can bind to Ocaratuzumab Biosimilar - Anti-MS4A1, CD20 mAb (cat. No.PX-TA1298) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450
Related products
Reviews
Il n’y a pas encore d’avis.